We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Protein Linked to Development of Drug Resistance by Breast Cancer Cells

By LabMedica International staff writers
Posted on 09 Jul 2012
Cancer researchers have found that the protein glucose-regulated protein 78 (GRP78), which is activated in some types of breast tumor cells, may be a key factor in the development of resistance to the primary chemotherapeutic agents tamoxifen and fulvestrant.

Treatment of breast cancer with antiestrogen drugs is designed to induce apoptosis in the more than 70% of breast cancers that express estrogen receptors. More...
However, in many cases, treatment is not effective or - after an initial positive response - the tumor becomes resistant to the drugs.

Investigators at Georgetown University (Washington DC, USA) examined the relationship between GRP78 activation and the development of anti-estrogen resistance by breast cancer cells.

They reported in the July 1, 2012, issue of the journal Cancer Research that tumors with acquired resistance to antiestrogen treatment overexpressed GRP78, while GRP78 overexpression was not observed in cases where the cancer cells were always resistant to the drugs. Knockdown of GRP78 restored antiestrogen sensitivity in resistant cells, and overexpression of GRP78 promoted resistance in sensitive cells.

At the molecular level, GRP78 integrated multiple cellular signaling pathways to inhibit apoptosis and stimulate prosurvival autophagy. GRP78 stimulation of autophagy enabled cancer cells to metabolize misfolded and potentially toxic proteins utilizing a mechanism known as the "unfolded protein response" or UPR.

"Since cancers often grow rapidly, tumors may lack enough energy to properly fold proteins into the correct orientation. These misfolded proteins accumulate in the cell and trigger UPR," said first author Dr. Katherine Cook, an oncology researcher at Georgetown University. "In normal cells UPR is protective, and if the stimuli last for an extended period of time, UPR becomes pro-death. But we have found cancers use the UPR to promote survival. Since GRP78 plays such an important role in drug resistance, it would be of great benefit to develop agents that target this protein."

That GRP78 does not play a role in breast cancers that never responded to antiestrogen therapy suggests that initial resistance and acquired resistance represent separate biological pathways. "This observation is consistent with the emerging concept that acquired resistance may be an adaptive response," said Dr. Cook.

Related Links:

Georgetown University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Spinal Fluid Cell Count Control
Spinalscopics
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.